Drug intelligence / Profile preview

alectinib + trastuzumab

Development stage: Preclinical
Lead developer: Roche
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Oral, Intravenous, Subcutaneous

Overview

This combination involves **alectinib**, a tyrosine kinase inhibitor targeting the anaplastic lymphoma kinase (ALK), and **trastuzumab**, a monoclonal antibody targeting the human epidermal growth factor receptor 2 (HER2). Alectinib is primarily used in the treatment of ALK-positive non-small cell lung cancer (NSCLC), while trastuzumab is used for HER2-positive breast cancer. The combination is explored for treating patients with both ALK-rearranged NSCLC and HER2-amplified or mutated cancers.

Targets

RET (Rearranged during transfection receptor tyrosine kinase)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ALK (Anaplastic lymphoma kinase receptor tyrosine kinase)

Beyond the preview

Go deeper on alectinib + trastuzumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on alectinib + trastuzumab.

Explore the full profile